The Russian company Intellogic, LLC, the developer of the leading platform for the analysis and processing of medical images using Botkin.AI artificial intelligence, quickly developed and added functionality for the study of pneumonia. A pilot project to test the functionality starts in the Yamal-Nenets Autonomous Region. The company expects that this will reduce risks and mitigate the possible consequences of the coronavirus COVID-19 epidemic. Intellogic, LLC is a portfolio company of RBV Capital venture fund created with the participation of RVC and R-Farm.
Due to the problematic epidemiological situation and the need for operational measures, the company decided to provide access to the new platform functionality for free for all medical organizations involved in the diagnosis and treatment of patients with COVID-19.
Epidemic study experience of coronavirus shows that computed tomography and radiography are the essential methods of complex diagnosis of the coronavirus infection. Severe cases of coronavirus and deaths from it are associated with the development of viral and bacterial (secondary) pneumonia in patients; therefore, these methods have become widely used in patients with the suspected coronavirus infection and suspected virus-related lung lesions. Examination results play a crucial role in the management and timely treatment of patients; as a result, the burden on radiologists in medical institutions increases dramatically.
One of the first pilot projects using the new platform functionality starts these days in the Yamal-Nenets Autonomous Region. The Department of Healthcare management of the Yamal-Nenets Autonomous Region decided to test the new Botkin.AI product to reduce the risk of missing signs of the coronavirus pneumonia. In the future, the product can be used to control the dynamics of the course of pneumonia, including in patients with coronavirus COVID-19. Shortly, it is planned to start similar projects in other regions.
Intellogic, LLC is a resident of Skolkovo. The scientific council of the company is headed by the President of the Russian Society of Radiology, the Head of the Course of Radiation Diagnostics at the Faculty of Fundamental Medicine, and the Head of the Department of Radiation Diagnostics at the ISRC of Lomonosov Moscow State University, MD, Professor Valentin Evgenievich Sinitsyn. The platform makes it possible to analyze images of digital radiography, computed tomography, and digital mammography. The company has already implemented the platform in more than ten regions of the Russian Federation, the CIS countries. It is also developing several international projects. The results of preliminary testing of technology for the analysis of pneumonia, published by the company in scientific articles, show an analysis accuracy of more than 99%, which is currently one of the best results in the world.